サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1769677

結節性痒疹の世界市場レポート2025年

Nodular Prurigo Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
結節性痒疹の世界市場レポート2025年
出版日: 2025年07月07日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

結節性痒疹市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.4％で、16億米ドルにまで拡大します。この予測成長の要因としては、標的治療の導入、希少皮膚疾患に対する研究開発投資の強化、患者教育やアドボカシー活動の強化、保険や償還の利用可能性の拡大、コンパニオン診断薬やバイオマーカーの開発などが挙げられます。予測期間中に予想される注目すべき動向としては、AI支援診断ツール、遺伝子編集の進歩、治療デリバリーにおけるナノテクノロジーの応用、革新的な生物学的療法、ウェアラブル・モニタリング技術の採用などが挙げられます。

標的治療に対する需要の高まりが結節性痒疹市場の成長を牽引すると予測されます。標的治療は、疾患の進行に関与する分子経路と特異的に相互作用するように設計された治療法です。その精度の高さ、副作用の軽減、患者の転帰の向上により、従来型広範囲な治療に代わる治療法として人気が高まっています。IL-4、IL-13、IL-31などの免疫経路が関与する明確なアンメットニーズを示す結節性痒疹の場合、標的生物製剤はこれらの炎症シグナルを効果的に遮断することができ、治療の成功につながります。 例えば、2023年10月、NHSイングランドは、英国でホルモン補充療法（HRT）が1,100万品目配合されたと報告しました。これは2021～2022年と比べて47％の増加であり、およそ230万人の患者が処方を受けており、前年比で29％の増加を示しています。このことは、標的療法に対する需要の増加という、より広範な傾向を反映しており、結節性痒疹（ノジュラー・プリュリゴ）市場の拡大にも寄与しています。

結節性痒疹市場の主要参入企業は、市場での存在感を高め、治療成果を向上させるため、規制当局の承認を重視しています。薬事承認とは、特定の医薬品や治療法の一般的な使用や販売を許可する、政府や規制当局からの正式な認可のことです。例えば、米国のバイオテクノロジー企業であるリジェネロン・ファーマシューティカルズインクは、2022年9月にデュピクセント（デュピルマブ）のFDA承認を取得し、結節性痒疹の治療として初めて、また唯一明示的に承認された治療となりました。この承認は、デュピクセントがプラセボと比較してかゆみと皮膚病変を有意に減少させたという第3相臨床検査（PRIMEとPRIME2）の成功を受けたものです。その結果、Dupixentは米国で結節性痒疹の治療として承認された唯一の薬剤となり、約7万5,000人の成人の痒みに対応することになりました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の結節性痒疹：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の結節性痒疹市場：成長率分析
  • 世界の結節性痒疹市場の実績：規模と成長、2019～2024年
  • 世界の結節性痒疹市場の予測：規模と成長、2024～2029年、2034年
  • 世界の結節性痒疹：総潜在市場規模（TAM）

第6章 市場セグメンテーション

  • 世界の結節性痒疹市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 慢性結節性痒疹
  • 急性結節性痒疹
  • 亜急性結節性痒疹
  • 世界の結節性痒疹市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 局所治療
  • 全身治療
  • 光線療法
  • 免疫抑制剤
  • 世界の結節性痒疹市場：患者人口統計別、実績と予測、2019～2024年、2024～2029年、2034年
  • 成人
  • 子供
  • 高齢者
  • 世界の結節性痒疹市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • 在宅医療
  • 専門クリニック
  • その他
  • 世界の結節性痒疹市場、慢性結節性痒疹のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 特発性慢性結節性痒疹
  • 皮膚疾患の原因
  • 神経障害の原因
  • 全身性疾患関連
  • 心因性痒疹
  • 世界の結節性痒疹市場、急性結節性痒疹のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 虫刺され
  • アレルギー反応
  • 薬剤性痒疹
  • 感染の誘因
  • 世界の結節性痒疹市場、亜急性結節性痒疹のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 慢性痒疹の治癒期
  • 炎症後痒疹
  • 一過性皮膚疾患
  • 環境刺激物質への反応

第7章 地域別・国別分析

  • 世界の結節性痒疹市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の結節性痒疹市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 結節性痒疹市場：競合情勢
  • 結節性痒疹市場：企業プロファイル
    • Merck & Co Inc.
    • Sanofi S.A.
    • GlaxoSmithKline plc
    • Amgen Inc.
    • Regeneron Pharmaceuticals Inc.

第31章 その他の大手企業と革新的企業

  • Astellas Pharma Inc.
  • Sun Pharmaceutical Industries Limited
  • Galderma S.A.
  • Galderma Laboratories L.P.
  • Incyte Corporation
  • Kyowa Kirin Co Ltd.
  • LEO Pharma A/S
  • Maruho Co Ltd.
  • Kiniksa Pharmaceuticals Ltd.
  • Keymed Biosciences Co Ltd.
  • Trevi Therapeutics Inc.
  • Fierce Pharma
  • Menlo Therapeutics Inc.
  • VYNE Therapeutics Inc.
  • Celldex Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 結節性痒疹市場、2029年：新たな機会を提供する国
  • 結節性痒疹市場、2029年：新たな機会を提供するセグメント
  • 結節性痒疹市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35992

Nodular prurigo, also referred to as prurigo nodularis, is a chronic dermatological condition characterized by extremely itchy, firm nodules that typically develop on areas such as the arms, legs, and torso. It is a persistent disorder of unknown origin involving immune, neurological, and inflammatory mechanisms, where continuous itching prompts repetitive scratching, leading to lesion aggravation, scarring, and often requiring long-term medical management by dermatologists.

The primary classifications of nodular prurigo include chronic nodular prurigo, acute nodular prurigo, and subacute nodular prurigo. Chronic nodular prurigo is a prolonged variant marked by the appearance of highly itchy, firm skin bumps. Treatments for the condition vary and may involve topical applications, systemic medications, phototherapy, and immunosuppressive agents. This condition affects various demographic groups, including adults, children, and the elderly, and treatment services are provided across different settings such as hospitals, homecare, specialty clinics, and others.

The nodular prurigo market research report is one of a series of new reports from The Business Research Company that provides nodular prurigo market statistics, including nodular prurigo industry global market size, regional shares, competitors with a nodular prurigo market share, nodular prurigo market segments, market trends and opportunities, and any further data you may need to thrive in the nodular prurigo industry. This nodular prurigo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nodular prurigo market size has grown strongly in recent years. It will grow from $1.17 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. Growth in the historical period was supported by an increase in dermatological consultations, greater awareness among skin specialists, unmet treatment needs, academic interest in the condition, and advancements in diagnostic capabilities.

The nodular prurigo market size is expected to see strong growth in the next few years. It will grow to $1.60 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. Contributing factors to this projected growth include the introduction of targeted therapies, enhanced R&D investment for rare skin conditions, more robust patient education and advocacy initiatives, broader insurance and reimbursement availability, and the development of companion diagnostics and biomarkers. Noteworthy trends anticipated during the forecast period include AI-assisted diagnostic tools, gene editing advancements, nanotechnology applications in treatment delivery, innovative biologic therapies, and the adoption of wearable monitoring technologies.

The rising demand for targeted therapies is anticipated to drive the growth of the nodular prurigo market. Targeted therapies are medical treatments designed to specifically interact with molecular pathways involved in disease progression. Their growing popularity stems from their precision, reduced side effects, and enhanced patient outcomes, making them favorable alternatives to traditional, broad-spectrum treatments. In the case of nodular prurigo, which presents a clear unmet need involving immune pathways such as IL-4, IL-13, and IL-31, targeted biologics can effectively block these inflammatory signals, leading to more successful treatment. For example, in October 2023, NHS England reported that 11 million hormone replacement therapy (HRT) items were prescribed in England-a 47% increase from 2021-22-with approximately 2.3 million patients receiving prescriptions, reflecting a 29% year-on-year growth. This illustrates the broader trend of increased demand for targeted therapies, which is contributing to the expansion of the nodular prurigo market.

Major players in the nodular prurigo market are emphasizing regulatory approvals to broaden their market presence and enhance treatment outcomes. Regulatory approvals involve official authorization from government or regulatory agencies, allowing the public use and marketing of specific drugs or therapies. For example, in September 2022, Regeneron Pharmaceuticals Inc., a biotechnology firm based in the U.S., obtained FDA approval for Dupixent (dupilumab), making it the first and only treatment explicitly approved for prurigo nodularis in adults. This approval followed successful Phase 3 trials-PRIME and PRIME2-which showed Dupixent significantly reduced itch and skin lesions compared to placebo. As a result, Dupixent emerged as the only medication in the U.S. with an approved indication for treating prurigo nodularis, addressing the needs of approximately 75,000 affected adults.

In April 2024, Incyte Corporation, a U.S.-based pharmaceutical company, formed a partnership with China Medical System Holdings Limited to advance the development and commercialization of Povorcitinib across Asia. The collaboration aims to support the treatment of various autoimmune and inflammatory dermatologic conditions, including non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria. China Medical System Holdings Limited, based in Hong Kong, is actively involved in treatments related to nodular prurigo.

Major players in the nodular prurigo market are Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Galderma S.A., Galderma Laboratories L.P., Incyte Corporation, Kyowa Kirin Co Ltd., LEO Pharma A/S, Maruho Co Ltd., Kiniksa Pharmaceuticals Ltd., Keymed Biosciences Co Ltd., Trevi Therapeutics Inc., Fierce Pharma, Menlo Therapeutics Inc., VYNE Therapeutics Inc., and Celldex Therapeutics Inc.

North America was the largest region in the nodular prurigo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nodular prurigo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nodular prurigo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nodular prurigo market consists of revenues earned by entities by providing services such as diagnosis and clinical evaluation, prescription of topical treatments, phototherapy, biologic therapies, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The nodular prurigo market also includes sales of products including oral antidepressants, JAK inhibitors, and topical calcineurin inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nodular Prurigo Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nodular prurigo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nodular prurigo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nodular prurigo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Chronic Nodular Prurigo; Acute Nodular Prurigo; Subacute Nodular Prurigo
  • 2) By Treatment Type: Topical Treatments; Systemic Treatments; Phototherapy; Immunosuppressants
  • 3) By Patient Demographics: Adults; Children; Elderly
  • 4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
  • Subsegments:
  • 1) By Chronic Nodular Prurigo: Idiopathic Chronic Nodular Prurigo; Secondary To Dermatologic Conditions; Neuropathic Causes; Systemic Disease-Associated; Psychogenic Prurigo
  • 2) By Acute Nodular Prurigo: Insect Bite-Induced; Allergic Reactions; Drug-Induced Prurigo; Infectious Triggers
  • 3) By Subacute Nodular Prurigo: Healing Phase Of Chronic Prurigo; Post-Inflammatory Prurigo; Transient Dermatoses; Reaction To Environmental Irritants
  • Companies Mentioned: Merck & Co Inc.; Sanofi S.A.; GlaxoSmithKline plc; Amgen Inc.; Regeneron Pharmaceuticals Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nodular Prurigo Market Characteristics

3. Nodular Prurigo Market Trends And Strategies

4. Nodular Prurigo Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Nodular Prurigo Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Nodular Prurigo PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Nodular Prurigo Market Growth Rate Analysis
  • 5.4. Global Nodular Prurigo Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Nodular Prurigo Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Nodular Prurigo Total Addressable Market (TAM)

6. Nodular Prurigo Market Segmentation

  • 6.1. Global Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chronic Nodular Prurigo
  • Acute Nodular Prurigo
  • Subacute Nodular Prurigo
  • 6.2. Global Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Treatments
  • Systemic Treatments
  • Phototherapy
  • Immunosuppressants
  • 6.3. Global Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Adults
  • Children
  • Elderly
  • 6.4. Global Nodular Prurigo Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-Users
  • 6.5. Global Nodular Prurigo Market, Sub-Segmentation Of Chronic Nodular Prurigo, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Idiopathic Chronic Nodular Prurigo
  • Secondary To Dermatologic Conditions
  • Neuropathic Causes
  • Systemic Disease-Associated
  • Psychogenic Prurigo
  • 6.6. Global Nodular Prurigo Market, Sub-Segmentation Of Acute Nodular Prurigo, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Insect Bite-Induced
  • Allergic Reactions
  • Drug-Induced Prurigo
  • Infectious Triggers
  • 6.7. Global Nodular Prurigo Market, Sub-Segmentation Of Subacute Nodular Prurigo, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Healing Phase Of Chronic Prurigo
  • Post-Inflammatory Prurigo
  • Transient Dermatoses
  • Reaction To Environmental Irritants

7. Nodular Prurigo Market Regional And Country Analysis

  • 7.1. Global Nodular Prurigo Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Nodular Prurigo Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nodular Prurigo Market

  • 8.1. Asia-Pacific Nodular Prurigo Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nodular Prurigo Market

  • 9.1. China Nodular Prurigo Market Overview
  • 9.2. China Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nodular Prurigo Market

  • 10.1. India Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nodular Prurigo Market

  • 11.1. Japan Nodular Prurigo Market Overview
  • 11.2. Japan Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nodular Prurigo Market

  • 12.1. Australia Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nodular Prurigo Market

  • 13.1. Indonesia Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nodular Prurigo Market

  • 14.1. South Korea Nodular Prurigo Market Overview
  • 14.2. South Korea Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nodular Prurigo Market

  • 15.1. Western Europe Nodular Prurigo Market Overview
  • 15.2. Western Europe Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nodular Prurigo Market

  • 16.1. UK Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nodular Prurigo Market

  • 17.1. Germany Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nodular Prurigo Market

  • 18.1. France Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nodular Prurigo Market

  • 19.1. Italy Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nodular Prurigo Market

  • 20.1. Spain Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nodular Prurigo Market

  • 21.1. Eastern Europe Nodular Prurigo Market Overview
  • 21.2. Eastern Europe Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nodular Prurigo Market

  • 22.1. Russia Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nodular Prurigo Market

  • 23.1. North America Nodular Prurigo Market Overview
  • 23.2. North America Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nodular Prurigo Market

  • 24.1. USA Nodular Prurigo Market Overview
  • 24.2. USA Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nodular Prurigo Market

  • 25.1. Canada Nodular Prurigo Market Overview
  • 25.2. Canada Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nodular Prurigo Market

  • 26.1. South America Nodular Prurigo Market Overview
  • 26.2. South America Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nodular Prurigo Market

  • 27.1. Brazil Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nodular Prurigo Market

  • 28.1. Middle East Nodular Prurigo Market Overview
  • 28.2. Middle East Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nodular Prurigo Market

  • 29.1. Africa Nodular Prurigo Market Overview
  • 29.2. Africa Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nodular Prurigo Market Competitive Landscape And Company Profiles

  • 30.1. Nodular Prurigo Market Competitive Landscape
  • 30.2. Nodular Prurigo Market Company Profiles
    • 30.2.1. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nodular Prurigo Market Other Major And Innovative Companies

  • 31.1. Astellas Pharma Inc.
  • 31.2. Sun Pharmaceutical Industries Limited
  • 31.3. Galderma S.A.
  • 31.4. Galderma Laboratories L.P.
  • 31.5. Incyte Corporation
  • 31.6. Kyowa Kirin Co Ltd.
  • 31.7. LEO Pharma A/S
  • 31.8. Maruho Co Ltd.
  • 31.9. Kiniksa Pharmaceuticals Ltd.
  • 31.10. Keymed Biosciences Co Ltd.
  • 31.11. Trevi Therapeutics Inc.
  • 31.12. Fierce Pharma
  • 31.13. Menlo Therapeutics Inc.
  • 31.14. VYNE Therapeutics Inc.
  • 31.15. Celldex Therapeutics Inc.

32. Global Nodular Prurigo Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nodular Prurigo Market

34. Recent Developments In The Nodular Prurigo Market

35. Nodular Prurigo Market High Potential Countries, Segments and Strategies

  • 35.1 Nodular Prurigo Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Nodular Prurigo Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Nodular Prurigo Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer